MARKET

GMAB

GMAB

Genmab
NASDAQ
32.52
-0.90
-2.69%
After Hours: 33.16 +0.64 +1.97% 19:11 12/29 EST
OPEN
32.89
PREV CLOSE
33.42
HIGH
33.00
LOW
32.51
VOLUME
1.50M
TURNOVER
--
52 WEEK HIGH
33.96
52 WEEK LOW
17.24
MARKET CAP
24.67B
P/E (TTM)
13.43
1D
5D
1M
3M
1Y
5Y
1D
Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets
Benzinga · 15h ago
Genmab ends development of late-stage oncology asset acasunlimab
Seeking Alpha · 17h ago
Analysts’ Top Healthcare Picks: Sanofi (SNYNF), Genmab (GMAB)
TipRanks · 17h ago
Genmab To Discontinue Clinical Development Of Acasunlimab To Focus On Priority Programs
NASDAQ · 18h ago
Genmab Drops Acasunlimab to Refocus Investment on Late-Stage Cancer Pipeline
TipRanks · 18h ago
Genmab A/S Plans To Discontinue Further Clinical Development Of Acasunlimab
Benzinga · 19h ago
GENMAB: DECISION DOES NOT IMPACT GENMAB'S FULL‑YEAR 2025 FINANCIAL GUIDANCE
Reuters · 19h ago
Weekly Report: what happened at GMAB last week (1222-1226)?
Weekly Report · 23h ago
More
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Webull offers Genmab A/S - ADR stock information, including NASDAQ: GMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GMAB stock methods without spending real money on the virtual paper trading platform.